R-etodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesis

Oncology Reports

Volumn 24, Issue 6, 2010, Pages 1487-1492

  Inoue, Takuya ^a   Murano, Mitsuyuki ^a   Yoda, Yukiko ^a   Kuramoto, Takanori ^a   Kakimoto, Kazuki ^a   Ishida, Kumi ^a   Kawakami, Ken ^a   Abe, Yosuke ^a   Morita, Eijiro ^a   Murano, Naoko ^a   Tokioka, Satoshi ^a   Maemura, Kentaro ^a   Umegaki, Eiji ^a   Higuchi, Kazuhide ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Cancer; Dextran sulfate sodium; E cadherin; Etodolac; Ulcerative colitis

Indexed keywords

CYCLOOXYGENASE 2; ETODOLAC; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SELECTIVITY; ENANTIOMER; ENZYME INHIBITION; FEMALE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CADHERINS; CARCINOMA; COLITIS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; ETODOLAC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, INBRED BALB C; SEVERITY OF ILLNESS INDEX; TUMOR BURDEN; UP-REGULATION;

EID: 78649417607     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001009     Document Type: Article

References (30)

1. Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Eng J Med 325: 1593-1596, 1991.
2. Thun MJ, Namboodiri MM, Calle EE, Flanders WD and Heath CW Jr: Aspirin use and risk of fatal cancer. Cancer Res 53: 1322-1327, 1993. (Pubitemid 23097110)
3. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC and Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609-614, 1995.
4. Reddy BS, Rao CV, Rivenson A and Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497, 1993.
5. Watson AJ: Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol 13: 591-597, 1998.
6. Sakamoto C: Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. J Gastroenterol 33: 618-624, 1998.
7. Ekbom A, Helmick C, Zack M and Adami HO: Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233, 1990.
8. Miner PB Jr: Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol 92: S1-S4, 1997.
9. Forrest K, Symmons D and Foster P: Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther 20: 1035-1043, 2004.
10. Inoue T, Murano M, Abe Y, Morita E, Murano N, Yasumoto S, Toshina K, Nishikawa T, Maemura K, Hirata I and Katsu K: Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis. J Gastroenterol Hepatol 22: 1474-1481, 2007.
11. Shi JM, Lai SG, Xu CJ, Duan GL and Li D: Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats. Acta Pharmacol Sin 25: 996-999, 2004.
12. Demerson CA, Humber LG, Abraham NA, Schilling G, Martel RR and Pace-Asciak C: Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J Med Chem 26: 1778-1780, 1983.
13. Behari J, Zeng G, Otruba W, Thompson MD, Muller P, Micsenyi A, Sekhon SS, Leoni L and Monga SP: R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol 46: 849-857, 2007. (Pubitemid 46529036)
14. Okamoto A, Shirakawa T, Bito T, Shigemura K, Hamada K, Gotoh A, Fujisawa M and Kawabata M: Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology 71: 156-160, 2008.
15. Liu W, Nakamura H, Tsujimura T, Cheng J, Yamamoto T, Iwamoto Y, Imanishi H, Shimomura S, Yamamoto T, Hirasawa T, Inagaki S, Nishiguchi S and Hada T: Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci 97: 768-773, 2006.
16. Wedemeyer J and Galli SJ: Decreased susceptibility of mast cell-deficient Kit(W)/Kit(W-v) mice to the development of 1, 2- dimethylhydrazine-induced intestinal tumors. Lab Invest 85: 388-396, 2005.
17. Riddell RH, Goldman H, Ransohof DF, Appleman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, Sommers SC and Yardley JH: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application. Human Pathol 14: 931-968, 1983.
18. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA and Sedergran DJ: Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine. Dig Dis Sci 38: 1722-1734, 1993.
19. Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, Kabeshima Y, Yorozuya K, Yamamoto K, Mukai M and Kitajima M: Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 45: 98-103, 2002. (Pubitemid 34072758)
20. Kotani T, Kobata A, Nakamura E, Amagase K and Takeuchi K: Roles of cyclooxygenase-2 and prostacyclin/IP receptors in mucosal defense against ischemia/reperfusion injury in mouse stomach. J Pharmacol Exp Ther 316: 547-555, 2006. (Pubitemid 43130980)
21. Inoue T, Murano M, Kuramoto T, Ishida K, Kawakami K, Abe Y, Morita E, Murano N, Toshina K, Nishikawa T, Maemura K, Shimamoto C, Hirata I, Katsu K and Higuchi K: Increased proliferation of middle to distal colonic cells during colorectal carcinogenesis in experimental murine ulcerative colitis. Oncol Rep 18: 1457-1462, 2007.
22. Schuhmacher C, Becker I, Oswald S, Atkinson MJ, Nekarda H, Becker KF, Mueller J, Siewert JR and Höfler H: Loss of immunohistochemical E-cadherin expression in colon cancer is not due to structural gene alterations. Virchows Arch 434: 489-495, 1999.
23. Aust DE, Terdiman JP, Willenbucher RF, Chew K, Ferrell L, Florendo C, Molinaro-Clark A, Baretton GB, Löhrs U and Waldman FM: Altered distribution of beta-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Mod Pathol 14: 29-39, 2001.
24. Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, Reed MW, Afonina IA, Rabinovitch PS, Stevens AC, Freng Z and Bronner MP: The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol 157: 737-745, 2000. (Pubitemid 32109366)
25. Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Eng J Med 356: 2131-2142, 2007.
26. Cooper HS, Murthy S, Kido K, Yoshitake H and Flanigan A: Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 21: 757-768, 2000.
27. Inoue T, Murano M, Kakimoto K, Okada T, Kawakami K, Ishida K, Abe Y, Morita E, Murano N, Toshina K, Maemura K, Hirata I and Higuchi K: Therapeutic effect of a cyclooxygenase- 2 selective inhibitor on colitis induced tumors. (in Japanese) Ulcer Res 35: 87-90, 2008.
28. Noda M, Tatsumi Y, Tomizawa M, Takama T, Mitsufuji S, Sugihara H, Kashima K and Hattori T: Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines. J Gastroenterol 37: 896-904, 2002.
29. Shinozaki M, Watanabe T, Kubota Y, Sawada T, Nagawa H and Muto T: High proliferative activity is associated with dysplasia in ulcerative colitis. Dis Colon Rectum 43: S34-S39, 2000.
30. Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W, Cottam HB, Leoni LM, Carson DA and Zhang XK: The Renantiomer of the non-steroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci USA 102: 2525-2530, 2005.